Ocrelizumab Mechanism of Action: How Ocrelizumab Works | Elicit
Ocrelizumab Mechanism of Action
How Ocrelizumab (Ocrevus) Works: CD20-directed cytolytic antibody targeting CD20-positive B cells to drive B-cell depletion.
Last updated:
March 2026
Quick Summary
Ocrelizumab (Ocrevus) is a humanized monoclonal antibody directed at CD20 used to treat multiple sclerosis. It is a CD20-directed cytolytic antibody that targets CD20-positive B cells; engagement of CD20 can cause cell lysis and B-cell depletion, which is beneficial in autoimmune conditions. It is indicated for relapsing forms of MS and for primary progressive MS.
Properties
| Details | |
|---|---|
| Generic Name | Ocrelizumab |
| Brand Names | Ocrevus |
| Drug Class | CD20 monoclonal antibody (CD20-directed cytolytic antibody) |
| Primary Target | CD20 (MS4A1) |
| Approved Indications | Relapsing forms of multiple sclerosis (RMS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS), primary progressive multiple sclerosis (PPMS) |
| Key Effect | Depletes CD20-positive B cells via CD20 engagement, causing cell lysis and B-cell depletion |
Development History
Ocrelizumab was developed by Genentech, a subsidiary of Roche, as a humanized anti-CD20 monoclonal antibody for B-cell–driven autoimmune disease. The pivotal program comprised two identical 96-week Phase 3 trials in relapsing MS, OPERA I and OPERA II, and a Phase 3 trial in primary progressive MS, ORATORIO. On the strength of this program, the FDA approved ocrelizumab on March 28, 2017 under the brand name Ocrevus for adults with relapsing forms of MS and PPMS.
Detailed Mechanism of Action
Ocrelizumab is an intravenously administered glycosylated IgG1 recombinant humanized anti-CD20 monoclonal antibody. Its therapeutic effect is anchored in the selective depletion of CD20-expressing immune cells, particularly peripheral B cells. The primary molecular target, CD20, is a transmembrane protein expressed on most cells of the human B-cell lineage but not on stem cells. Antibody engagement leads to Antibody-dependent cellular cytotoxicity (ADCC) as the dominant mechanism.
Clinical Relevance
Approved Indications
- Relapsing Forms of Multiple Sclerosis (RMS): Indicated for adults with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
- Primary Progressive Multiple Sclerosis (PPMS): The first therapy approved for PPMS.
Key Drug Interactions
- Live or Live-Attenuated Vaccines: Not recommended during ocrelizumab therapy.
- Inactivated (Non-Live) Vaccines: Ocrelizumab attenuates antibody responses even to non-live vaccines.
Contraindications
- Active Hepatitis B Virus (HBV) Infection: Requires screening before initiation.
- Severe Active Infections: Initiation should be deferred until the infection is resolved.
Emerging Indications
Neurology
- Neuromyelitis Optica Spectrum Disorder (Phase 2, completed): Evaluated ocrelizumab in NMOSD patients.
- Amyotrophic Lateral Sclerosis (Phase 2, active): Assessing ocrelizumab in ALS patients with neuroinflammatory biomarkers.
Immunology
- Lupus Nephritis (Phase 3, terminated): Evaluated ocrelizumab in lupus nephritis but terminated early.
- Primary Sjögren's Syndrome (Phase 2, completed): Indicated improvements observed but development not advanced.
Clinical Trials of Ocrelizumab
| Trial Name | Phase | N Enrolled | Intervention | Indication | Primary Endpoint | Key Result | Status |
|---|---|---|---|---|---|---|---|
| CONSONANCE | Phase 3b | 629 | Ocrelizumab administered every 24 weeks | Primary and Secondary Progressive MS | No Evidence of Progression (NEP) over one year | 75% achieved NEP | Ongoing |
| GAVOTTE | Phase 3b | 753 | High-dose ocrelizumab vs standard | Primary Progressive MS | Time to onset of composite confirmed disability progression | No improvement over 600 mg | Ongoing |
| OCARINA II | Phase 3 | 236 | Ocrelizumab SC vs IV | RMS/PPMS | Serum concentration-time curve from baseline to Week 12 | Ongoing |
Open Research Questions
What drives individual variability in hypogammaglobulinemia and serious infection risk over years of continuous anti-CD20 therapy?
What mechanisms underlie the heterogeneous humoral vaccine response in ocrelizumab-treated patients?